The market for initial public offerings is heading into the home stretch this week with Samsara, an internet of things company, and biotech Genenta Science opening for trading Wednesday.
Samsara stock rose by more than 7%, while Genenta slipped below its IPO price.
Roughly six companies were expected to list their shares this week. Sidus Space (ticker: SIDU), a satellite company, soared nearly 144% during its debut Wednesday, while Fresh Vine Wine (VINE), a producer of low-carb wine, dropped below its offer price. Two companies, biotechs Bionomics and Immix Biopharma, are slated to begin trading Thursday.
Samsara (ticker: IOT) is the most notable IPO this week. Shares of the Internet-of-things firm kicked off at $24.90 and closed at $24.70, up $1.70 from its offer price.
The company raised $805 million after selling 35 million shares at $23 each, the top of its $20-to-$23 price range.
At $24.70 a share, Samsara’s valuation is $12.3 billion. Morgan Stanley, Goldman Sachs, J.P.Morgan, and Allen & Co. are lead underwriters on the deal.
Founded in 2015 by CEO Sanjit Biswas and John Bicket, chief technology officer, San Francisco-based Samsara provides a connected operations cloud and sensors that are used by companies to manage their vehicle fleets and industrial operations. (Biswas and Bicket previously founded cloud infrastructure start-up Meraki which they sold to Cisco Systems (CSCO) in 2012.)
Samsara’s technology collects data including video footage, people, and motion-detection, GPS location, and energy consumption. Companies can use this information to improve safety, lower insurance costs, and reduce the need for manual oversight and judgment, the prospectus said.
Samsara has raised $930 million in funding, according to Crunchbase. This includes a $400 million funding round in May 2020 from investors including asset manager AllianceBernstein, investment firm Franklin Templeton, private-equity firms General Atlantic and Warburg Pincus, along with hedge fund Sands Capital Management, a statement from that time said.
Andreessen Horowitz, a venture firm that often invests in technology startups, will have 17.5% of Samsara total voting power, while General Catalyst, a venture-capital firm, will hold nearly 10%.
Shares of Genenta Science (GNTA) opened at $10.05 and ended at $11, down more than 4% from its offer price.
Genenta Science’s much smaller IPO collected about $36 million. The Milan, Italy-based biotech sold 2.4 million American depositary shares, or ADSs, at $11.50 each, the middle of its $10.50-to-$12.50 price range. Each ADS represents one ordinary share. Roth Capital Partners is underwriter on the deal.
Genenta is developing hematopoietic stem-cell gene therapies. Its lead product candidate, Temferon, treats glioblastoma multiforme, or GBM, a common malignant primary brain tumor. The company said it is currently conducting a Phase 1/2a dose-escalation clinical trial with Temferon in newly diagnosed GBM patients in Italy.
精彩评论